Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fsh + lh + cetrorelix
- Development stage
- Phase 4
- Lead developer
- NuGen Medical Devices
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
This combination therapeutic regimen is used in assisted reproductive technology (ART) for the treatment of female infertility, particularly in women identified as "poor responders" undergoing in vitro fertilization (IVF). The protocol involves the administration of recombinant follicle-stimulating hormone (FSH) and recombinant luteinizing hormone (LH) to stimulate follicular development and maturation. To prevent a premature luteinizing hormone surge and subsequent ovulation before oocyte retrieval, cetrorelix, a gonadotropin-releasing hormone (GnRH) antagonist, is administered. This specific combination was evaluated by Bioroma in clinical trials comparing various ovarian stimulation protocols, such as the flexible GnRH antagonist protocol and the microdose GnRH agonist protocol, to optimize pregnancy and live birth rates in patients with diminished ovarian reserve.
- Other names
- follitropin alfa + lutropin alfa + cetrorelixrecombinant FSH + recombinant LH + cetrorelix
02
Targets
FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on fsh + lh + cetrorelix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fsh + lh + cetrorelix.